Project: Re-Define Regenerative Medicine with a Point-Of-Care Tissue Production Technology
| Acronym | RegenMed2.0 (Reference Number: 114105) |
| Duration | 01/09/2020 - 01/09/2022 |
| Project Topic | The scope of the project is to validate a novel Point-Of-Care (POC) tissue production solution that will be at the core of a disruption in the field of personalized regenerative medicine. The solution aims to deliver a patient specific graft manufactured bed-side, starting with a small healthy biopsy of patient’s own tissue, first converted into micrografts to be, in a second step, valorized as a transplant graft within a “Sound Induced Morphogenesis” biofabrication process. Refer Appendix1 |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | AO Research Institute Davos | Partner | Switzerland |
| 2 | mimiX Biotherapeutics | Coordinator | Switzerland |
| 3 | Rigenera HBW | Partner | Italy |